☆ 4.4 Article

Efficacy and safety of eptinezumab for migraine prevention in patients with prior preventive treatment failures: subgroup analysis of the randomized, placebo-controlled DELIVER study

CEPHALALGIA (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Clinical Neurology

Adding eptinezumab to brief patient education to treat chronic migraine and medication-overuse headache: Protocol for RESOLUTION-A phase 4, multinational, randomized, double-blind, placebo-controlled study

Rigmor H. Jensen et al.

Summary: This article introduces the treatment method for medication-overuse headache by using preventive migraine treatment and withdrawal of overused medication. The design of a clinical trial is reported to evaluate the effectiveness of eptinezumab as a preventive migraine treatment for medication-overuse headache. The study will include 570 participants with dual diagnoses of chronic migraine and medication-overuse headache, and compare the impact on headache frequency and quality of life between two treatment groups.

FRONTIERS IN NEUROLOGY (2023)

添加到收藏夹

Article Pharmacology & Pharmacy

Impact of Baseline Characteristics on the Efficacy and Safety of Eptinezumab in Patients With Migraine: Subgroup Analyses of PROMISE-1 and PROMISE-2

Vincent Martin et al.

Summary: In the PROMISE-1 and PROMISE-2 clinical trials, eptinezumab 100 mg and 300 mg demonstrated significant efficacy in reducing monthly migraine days. The impact of baseline demographic and migraine characteristics on treatment efficacy and safety was evaluated, with no clear pattern identified except for the obesity subgroup.

CLINICAL THERAPEUTICS (2022)

添加到收藏夹

Article Clinical Neurology

Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): a multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial

Messoud Ashina et al.

Summary: This study investigated the safety and efficacy of eptinezumab for patients with migraine and two-to-four previous preventive treatment failures, showing significant migraine preventive effects compared to placebo.

LANCET NEUROLOGY (2022)

添加到收藏夹

Correction Clinical Neurology

GBD 2016 Headache Collaborators. Global, regional, and national burden of migraine and tension-type headache, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016 (vol 17, pg 954, 2018)

Ali H. Mokdad

LANCET NEUROLOGY (2021)

添加到收藏夹

Article Clinical Neurology

The prevalence and impact of migraine and severe headache in the United States: Updated age, sex, and socioeconomic-specific estimates from government health surveys

Rebecca Burch et al.

Summary: Accurate estimates of the burden of migraine and severe headache are crucial for evidence-based decision-making about workforce needs and health resource distribution. The prevalence of migraine in the US has remained stable, with a higher impact in women of childbearing age and those of lower socioeconomic status. Many adults with migraine or severe headaches are disadvantaged, highlighting the need for improved funding for treatment provision and research to reduce the future burden of disease.

HEADACHE (2021)

添加到收藏夹

Article Clinical Neurology

Impact of age and sex on the efficacy of fremanezumab in patients with difficult-to-treat migraine: results of the randomized, placebo-controlled, phase 3b FOCUS study

Antoinette MaassenVanDenBrink et al.

Summary: The efficacy of fremanezumab in reducing migraine and headache days, acute medication use, and disability was demonstrated in patients with difficult-to-treat migraine, regardless of age or sex, according to the FOCUS study.

JOURNAL OF HEADACHE AND PAIN (2021)

添加到收藏夹

Article Clinical Neurology

Efficacy of galcanezumab in patients with migraine and history of failure to 3-4 preventive medication categories: subgroup analysis from CONQUER study

Rose Okonkwo et al.

Summary: Galcanezumab demonstrated significant efficacy in patients with episodic migraine (EM) or chronic migraine (CM) who had failed 3-4 prior preventive medication categories, showing reductions in monthly migraine headache days, increased response rates, and improvements in patient functioning and disability.

JOURNAL OF HEADACHE AND PAIN (2021)

添加到收藏夹

Article Clinical Neurology

Long-term safety and tolerability of eptinezumab in patients with chronic migraine: a 2-year, open-label, phase 3 trial

David Kudrow et al.

Summary: In the PREVAIL study, eptinezumab demonstrated a favorable safety profile and improvements in patient-reported outcomes over 2 years in adults with chronic migraine. The study also showed limited long-term immunogenicity of eptinezumab.

BMC NEUROLOGY (2021)

添加到收藏夹

Article Clinical Neurology

Fremanezumab for the Preventive Treatment of Migraine: Subgroup Analysis by Number of Prior Preventive Treatments with Inadequate Response

Ladislav Pazdera et al.

Summary: The study evaluated the efficacy of monthly or quarterly fremanezumab in patients with chronic or episodic migraine who had inadequate response to 2 to 4 prior migraine preventive medications. Results showed significant improvements in efficacy with fremanezumab compared to placebo, even in patients who had previously experienced inadequate response to 4 different classes of migraine preventive medications. No significant treatment-by-subgroup interactions were observed, and adverse events were comparable between placebo and fremanezumab.

CEPHALALGIA (2021)

添加到收藏夹

Article Clinical Neurology

Safety and tolerability of eptinezumab in patients with migraine: a pooled analysis of 5 clinical trials

Timothy R. Smith et al.

Summary: The study evaluated the safety and tolerability of the humanized anti-CGRP monoclonal antibody eptinezumab in patients with migraine across five large-scale clinical trials. The results showed a favorable safety and tolerability profile of eptinezumab in adults with migraine, with most adverse events being mild or moderate in severity.

JOURNAL OF HEADACHE AND PAIN (2021)

添加到收藏夹

Review Medicine, General & Internal

Headache Disparities in African-Americans in the United States: A Narrative Review

Larry Charleston

Summary: This paper discusses racial/ethnic disparities in headache medicine for African-Americans in the US. Studies show that healthcare services for migraine treatment are underutilized, diagnoses are inaccurate, communication with physicians is poorer, and migraine burden is higher for African-Americans compared to non-Hispanic Whites. Research is needed to address these disparities.

JOURNAL OF THE NATIONAL MEDICAL ASSOCIATION (2021)

添加到收藏夹

Article Clinical Neurology

Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1)

Messoud Ashina et al.

CEPHALALGIA (2020)

添加到收藏夹

Article Pharmacology & Pharmacy

Eptinezumab: First Approval

Sohita Dhillon

DRUGS (2020)

添加到收藏夹

Article Clinical Neurology

Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2

Richard B. Lipton et al.

NEUROLOGY (2020)

添加到收藏夹

Article Clinical Neurology

Eptinezumab for the prevention of chronic migraine: efficacy and safety through 24 weeks of treatment in the phase 3 PROMISE-2 (Prevention of migraine via intravenous ALD403 safety and efficacy-2) study

Stephen Silberstein et al.

JOURNAL OF HEADACHE AND PAIN (2020)

添加到收藏夹

Article Clinical Neurology

Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial

Wim M. Mulleners et al.

LANCET NEUROLOGY (2020)

添加到收藏夹

Article Pharmacology & Pharmacy

Eptinezumab for the Prevention of Episodic Migraine: Sustained Effect Through 1 Year of Treatment in the PROMISE-1 Study

Timothy R. Smith et al.

CLINICAL THERAPEUTICS (2020)

添加到收藏夹

Article Medicine, General & Internal

Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial

Michel D. Ferrari et al.

LANCET (2019)

添加到收藏夹

Review Clinical Neurology

Migraine and the trigeminovascular system-40 years and counting

Messoud Ashina et al.

LANCET NEUROLOGY (2019)

添加到收藏夹

Article Clinical Neurology

Migraine Epidemiology, Burden, and Comorbidity

Rebecca C. Burch et al.

NEUROLOGIC CLINICS (2019)

添加到收藏夹

Article Clinical Neurology

Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults

Cristina Tassorelli et al.

CEPHALALGIA (2018)

添加到收藏夹

Article Clinical Neurology

Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition

Jes Olesen

CEPHALALGIA (2018)

添加到收藏夹

Article Clinical Neurology

Global, regional, and national burden of meningitis, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016

Joseph Raymond Zunt et al.

LANCET NEUROLOGY (2018)

添加到收藏夹

Article Clinical Neurology

Global, regional, and national burden of migraine and tension-type headache, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016

Lars Jacob Stovner et al.

LANCET NEUROLOGY (2018)

添加到收藏夹

Article Medicine, General & Internal

Health and quality of life in patients with medication overuse headache syndrome after standardized inpatient rehabilitation A cross-sectional pilot study

Thomas Benz et al.

MEDICINE (2017)

添加到收藏夹

Article Clinical Neurology

Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial

David W. Dodick et al.

LANCET NEUROLOGY (2014)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.